Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 53
Filter
1.
Z Gastroenterol ; 41(4): 325-8, 2003 Apr.
Article in German | MEDLINE | ID: mdl-12695938

ABSTRACT

Infiltrative, inflammatory or thromboembolic processes in the parenchyma of the spleen can cause a functional loss of the organ. This phenomenon is called functional asplenia and occurs as a complication especially in sickle cell disease, lupus erythematosus and after bone marrow transplantation. We present the case of a patient with Crohn's disease under immunosuppressive therapy who developed a spontaneous covered spleen rupture in the course of a septic shock with DIG due to a Varizella zoster infection. Later on, sonography showed a diminution of the spleen size. No flow signals could be derived by colour doppler measurements from the spleen. Because of the colour doppler findings we suspected a functional asplenia which was then verified by spleen scintigraphy and Howell-Jolly-Bodies in the blood count. Remarkably, the Crohn's disease remains in complete remission since the development of the functional asplenia (for 4 years now). The underlying pathomechanism remains unclear.


Subject(s)
Crohn Disease/diagnostic imaging , Herpes Zoster/diagnostic imaging , Opportunistic Infections/diagnostic imaging , Splenic Infarction/diagnostic imaging , Splenic Rupture/diagnostic imaging , Adult , Atrophy , Azathioprine/administration & dosage , Azathioprine/adverse effects , Crohn Disease/drug therapy , Crohn Disease/immunology , Drug Therapy, Combination , Follow-Up Studies , Herpes Zoster/immunology , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Male , Opportunistic Infections/immunology , Prednisolone/administration & dosage , Prednisolone/adverse effects , Rupture, Spontaneous , Spleen/diagnostic imaging , Spleen/pathology , Splenic Infarction/immunology , Splenic Rupture/immunology , Ultrasonography, Doppler, Color
2.
Rofo ; 174(9): 1154-7, 2002 Sep.
Article in German | MEDLINE | ID: mdl-12221575

ABSTRACT

PURPOSE: To determine whether the application of secretin improves the depiction of the normal pancreatic duct and to document the time course of any possible improved visualisation. PATIENTS AND METHODS: Twenty-eight patients with a normal pancreatic ductal system, proved by ERCP, were prospectively enrolled in our study. MRCP was carried out in a 1.0 Tesla unit using a thick slab single-shot turbo-echo sequence (TR: infinity, TE: 1100 ms, FA: 150 degrees, slab thickness: 65 mm). Following acquisition of a non-enhanced image, 1 clinical unit/kg bodyweight of secretin was injected intravenously. During the subsequent ten minutes the MR measurement was repeated every 30 seconds. The images were independently evaluated by two investigators. RESULTS: The improvement in quality after administration of secretin was statistically significant for both investigators (p < 0.05), but no significant difference was found between both investigators concerning the quality of the images (p = 0.49). Prior to the secretin application, the entire ductal system only be evaluated in ten cases (35.7 %) by both investigators, afterwards in 26 cases (92.9 %). Improvement was achieved after a mean time of 1.5 minutes and lasted until the ninth minute. CONCLUSION: Intravenous application of secretin improves image quality of MRCP also in patients with no pancreatic pathology. Improvement begins after 1.5 minutes and lasts for about seven minutes.


Subject(s)
Cholangiography/methods , Cholangiopancreatography, Endoscopic Retrograde/methods , Image Enhancement/methods , Magnetic Resonance Imaging/methods , Pancreatic Ducts/anatomy & histology , Secretin , Adult , Aged , Female , Humans , Male , Middle Aged , Reference Values
3.
Rofo ; 174(3): 291-6, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11885005

ABSTRACT

AIMS: To show the ability of magnetic resonance hydrometry (MRH) to quantify the pancreatic secretion after secretin stimulation in order to distinguish between physiological excretion and reduced output in chronic pancreatitis. METHODS: MRH images were acquired in a 1.0-T-clinical scanner using a body-array coil and a heavily T2-weighted standard single-shot TSE sequence. Thirty-one patients (14 male/17 female) who routinely underwent ERCP for suspected choledocholithiasis (n = 22), recurring abdominal pain (n = 1), icterus (n = 6 and suspected pancreatitis (n = 2) were included. During the investigation 1 CU/kg BW secretin were administered intravenously. Secreted volume of fluid, start of secretion, achievement of a plateau of secretion and a combined score of these parameters (MRH score) were assessed and evaluated. Sensitivity and specificity were calculated for these parameters. RESULTS: 27 patients had no pancreatic pathology, and four suffered from chronic pancreatitis. Patients without pancreatic disorders produced a mean pancreatic fluid volume of 183 plus minus 86 mL, whereas patients with chronic pancreatitis secreted 61 +/- 39 mL. Secretion started after a mean time of 95 +/- 94 seconds (no pancreatic impairment) and 62 +/- 13 seconds (chronic pancreatitis). The MRH score achieved a high accuracy in the detection of chronic pancreatitis. CONCLUSIONS: Our study demonstrated the feasibility of measuring pancreatic output by MRH after stimulation with secretin. Moreover, a distinction between normal secretion and patients with chronic pancreatitis is possible.


Subject(s)
Exocrine Pancreatic Insufficiency/diagnosis , Image Enhancement/methods , Magnetic Resonance Imaging/methods , Pancreatic Function Tests/methods , Pancreatitis/diagnosis , Adult , Aged , Cholangiopancreatography, Endoscopic Retrograde , Chronic Disease , Female , Gallstones/diagnosis , Humans , Image Processing, Computer-Assisted , Male , Middle Aged , Pancreatic Juice/metabolism , Prospective Studies , Reference Values , Secretin , Sensitivity and Specificity
4.
Gut ; 50(1): 52-60, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11772967

ABSTRACT

BACKGROUND AND AIMS: Recently, novel somatostatin receptor (sstr) subtype specific ligand analogues have been developed for medical treatment of neuroendocrine tumours expressing different sstrs (sstr1-5). At present, individual expression patterns of sstr subtypes are based on methods such as in situ hybridisation and polymerase chain reaction at the transcriptional level. Therefore, we generated subtype specific antibodies against sstr1, 2A, 3, and 5 and analysed their presence, cellular localisation, distribution, and expression pattern in 33 gastrinomas, 36 insulinomas, and 35 tumours associated with a carcinoid syndrome by immunohistochemistry at the translational level. METHODS: Western blotting experiments were performed in the normal human pancreas used as a reference organ and in tumour tissues; at the cellular level, sstrs were localised by immunohistochemistry in tissue paraffin sections. RESULTS: In western blot analyses, the antibodies identified the respective receptors in their correct molecular range in extracts of the pancreas and neuroendocrine tumours. Using immunohistochemistry and immunofluorescence, the antibodies specifically detected the receptors in islet cells of the normal pancreas. Immunohistochemistry in the tumours revealed that all investigated sstr subtypes were highly expressed in the different tumour types. The frequency and expression pattern of the individual sstr subtypes varied considerably not only between the different tumour types but also in each patient. CONCLUSIONS: We conclude that immunohistochemistry with subtype specific antibodies can be used in clinical routine work to analyse sstr expression patterns for each patient before treatment and to facilitate well directed individual medical therapy by administering subtype specific somatostatin analogues.


Subject(s)
Neuroendocrine Tumors/immunology , Receptors, Somatostatin/immunology , Antibody Specificity , Blotting, Western , Chromatography, High Pressure Liquid , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Humans , Immunization
5.
Histochem Cell Biol ; 115(2): 131-45, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11444148

ABSTRACT

Cystic fibrosis transmembrane conductance regulator (CFTR) is a channel and regulator protein that is crucially involved in transepithelial ion transport. In the exocrine pancreas, the CFTR-mediated secretion of an electrolyte-rich fluid is a major but as yet incompletely understood function. We show here that the peptide guanylin is a specific activator of CFTR function in the human pancreas implicating regulation of pancreatic electrolyte secretion. Guanylin and its affiliated signaling and effector proteins including guanylate cyclase C, cGMP-dependent protein kinase II, CFTR, and the epithelial Cl-/HCO3- exchanger, anion exchanger 2, are highly expressed in the human pancreas. Guanylin is localized specifically to the typical centroacinar cells and proximal duct cells which, based on its additional presence in the pancreatic juice, is obviously released luminally into the pancreatic ducts. The guanylin receptor and the respective functional downstream proteins are all confined to the apical membrane of the duct cells implicating an as yet unknown route of luminal regulatory pathway of electrolyte secretion in the ductal system. Functional studies in two different human pancreatic duct cell lines expressing the CFTR Cl- channel that is functionally intact in CAPAN-1 cells but defective (delta F508) in CFPAC-1 cells clearly identify guanylin as a specific regulator of pancreatic CFTR channel function. Whole-cell patch-clamp recordings in CAPAN-1 cells revealed that forskolin induces an increase of Cl- conductance mediated by cAMP. In contrast, guanylin increased Cl- conductance in the same cells via cGMP but not cAMP; the respective membrane current was largely blockable by the sulfonylurea glibenclamide. In CFPAC-1 cells, however, neither guanylin nor forskolin produced a current activation. Based on the present findings we conclude that guanylin is an intrinsic pancreatic regulator of Cl- current activation in pancreatic duct cells via cGMP and CFTR. Remarkably, in the pancreas guanylin may exert its function through an intriguing luminocrine mode via the pancreatic juice.


Subject(s)
Cyclic GMP/metabolism , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Electrolytes/metabolism , Gastrointestinal Hormones , Pancreas/metabolism , Peptides/metabolism , Cyclic GMP-Dependent Protein Kinase Type II , Cyclic GMP-Dependent Protein Kinases/metabolism , Cystic Fibrosis Transmembrane Conductance Regulator/analysis , Gene Expression/physiology , Guanylate Cyclase/analysis , Guanylate Cyclase/genetics , Guanylate Cyclase/metabolism , Humans , Natriuretic Peptides , Pancreas/chemistry , Pancreas/cytology , Pancreatic Ducts/chemistry , Pancreatic Ducts/cytology , Pancreatic Ducts/metabolism , Pancreatic Juice/metabolism , Patch-Clamp Techniques , Peptides/analysis , Peptides/genetics , RNA, Messenger/analysis , Receptors, Enterotoxin , Receptors, Guanylate Cyclase-Coupled , Receptors, Peptide/analysis , Receptors, Peptide/genetics , Receptors, Peptide/metabolism , Signal Transduction/physiology
6.
Regul Pept ; 97(2-3): 187-94, 2001 Mar 02.
Article in English | MEDLINE | ID: mdl-11164955

ABSTRACT

To establish indirect in-situ PCR for the detection of intestinal peptide hormones, rat intestine and a murine intestinal tumor cell line, STC 1, were used. The results exhibited intensive staining of GIP-producing K-cells. Paraformaldehyde-fixed cryostat sections yielded the best results in signal to background ratio with RT-PCR in-situ hybridization. Moreover, it was possible to elevate the positive staining signal and to reduce background staining. Digoxigenin-labeled in-situ hybridization served as a control for specificity and sensitivity of GIP (glucose-dependent insulinotropic peptide) mRNA expression on cryostat as well as paraffin sections. In conclusion, this RT-PCR in-situ hybridization protocol proves to be a specific, sensitive and reliable non-radioactive technique for the detection of intestinal peptide hormone mRNA, especially in tissues or tumor cells where the application of ISH is limited.


Subject(s)
Gastric Inhibitory Polypeptide/analysis , In Situ Hybridization/methods , Intestines/chemistry , Reverse Transcriptase Polymerase Chain Reaction , Animals , Base Sequence , DNA Primers , Gastric Inhibitory Polypeptide/genetics , Mice , Rats
7.
Cell Tissue Res ; 299(2): 289-98, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10741470

ABSTRACT

Gastrin stimulates gastric acid secretion by acting on the cholecystokinin B/gastrin receptor (CCK-BR). The localization of this receptor at the cellular level showed conflicting results in animal studies and has not been described in man by immunohistochemistry. The aim of the present study is to characterize the precise cellular location of the CCK-BR in the human stomach. Polyclonal antisera were raised against different epitopes of the CCK-BR molecule and used for immunohistochemical investigations. CCK-BR mRNA was detected in paraffin tissue sections by the highly sensitive method of in situ reverse transcriptase-polymerase chain reaction (RT-PCR). Using immunohistochemistry, CCK-BR could successfully be localized in gastric parietal cells. In the majority of parietal cells, CCK-BR immunoreactivity was present a he basolateral cell membrane domain. In some parietal cells, a granular pattern of immunoreactivity was exclusively confined to the cytoplasm of the cells. CCK-BR mRNA was found in parietal cells and in enterochromaffin-like (ECL) cells by means of in situ RT-PCR. No expression of CCK-BR was found in the gastric antral mucosa. Our data support the concept that gastrin stimulates gastric acid secretion directly via CCK-B receptors on parietal cells and indirectly by inducing histamine release from histamine-containing ECL cells, which contributes to acid secretion by parietal cells.


Subject(s)
Gastric Mucosa/metabolism , Receptors, Cholecystokinin/biosynthesis , Amino Acid Sequence , Cell Polarity , Cytoplasm/chemistry , Enterochromaffin Cells/chemistry , Epitopes/immunology , Gastric Acid/metabolism , Gastric Fundus/cytology , Gastric Fundus/metabolism , Gastric Mucosa/cytology , Gene Expression Regulation , Humans , Immune Sera , Molecular Sequence Data , Parietal Cells, Gastric/chemistry , Receptors, Cholecystokinin/analysis , Receptors, Cholecystokinin/genetics , Receptors, Cholecystokinin/immunology , Reverse Transcriptase Polymerase Chain Reaction , Stomach/cytology
8.
Digestion ; 60(5): 428-39, 1999.
Article in English | MEDLINE | ID: mdl-10473967

ABSTRACT

BACKGROUND: Gastric enterochromaffin-like (ECL) cells selectively express the vesicular monoamine transporter (VMAT) VMAT2, and enterochromaffin (EC) cells the VMAT1 isoform. AIMS: We investigated whether VMAT isoform selection indicates the origin of endocrine hyperplasia and neoplasia from oxyntic ECL or EC cells and may be of prognostic significance in different types of gastric carcinoids. METHODS: Tissue from patients with chronic atrophic gastritis (CAG), Zollinger-Ellison-syndrome (ZES), gastric carcinoids and neuroendocrine carcinoma (NEC) was investigated by immunohistology and in situ hybridization. RESULTS: Endocrine cells forming diffuse, linear, and micronodular hyperplasia in CAG and ZES, as well as oxyntic microcarcinoids expressed both VMAT2 and chromogranin A (CgA) but neither VMAT1 nor serotonin. In five of six sporadic carcinoids VMAT2 and CgA but not VMAT1 were detected. One carcinoid was copositive for VMAT1 and serotonin but negative for VMAT2. Electron microscopy confirmed the VMAT2-positive tumors as ECLoma and the VMAT1-immunoreactive carcinoid as EComa. CONCLUSIONS: VMAT2 and VMAT1 are reliable markers for differentiation of gastric endocrine hyperplasia and neoplasia from ECL and EC cells, respectively. The significance of VMAT2 and VMAT1 as prognostic markers lies in the relatively poor prognosis for EComa compared to ECLoma, characterized by VMAT2 positivity. The absence of both VMAT2 and VMAT1 in NEC may indicate poor prognosis.


Subject(s)
Biogenic Monoamines/metabolism , Carcinoid Tumor/metabolism , Multiple Endocrine Neoplasia Type 1/metabolism , Stomach Neoplasms/metabolism , Zollinger-Ellison Syndrome/metabolism , Adult , Aged , Carcinoid Tumor/pathology , Enterochromaffin Cells/metabolism , Enterochromaffin Cells/pathology , Female , Humans , Hyperplasia , Immunohistochemistry , In Situ Hybridization , Male , Microscopy, Electron , Middle Aged , Multiple Endocrine Neoplasia Type 1/pathology , Stomach Neoplasms/pathology , Zollinger-Ellison Syndrome/pathology
10.
Regul Pept ; 70(2-3): 143-8, 1997 Jun 18.
Article in English | MEDLINE | ID: mdl-9272626

ABSTRACT

Transient expression of pancreatic gastrin corresponds to a period of rapid islet cell development. After birth gastrin expression silencing is coincidental with islet cell terminal differentiation, while persistent expression is accompanied with nesidioblastosis and reexpression observed in islet cell tumors. Experiments with transgenic animals suggested that gastrin might act synergistically with growth factors to stimulate islet cell development. The present study intended to establish an in vitro cell culture model to analyse the molecular events controlling gastrin gene activation and repression dependent on islet cell differentiation. Sodium butyrate, a proliferation-arresting compound has previously been shown to differentiate insulinoma cells while increasing insulin production. The present paper demonstrates concomitant transient increase in gastrin mRNA, intracellular and secreted gastrin during sodium butyrate treatment. Increased gastrin expression was due to activation or derepression of gastrin promoter activity as revealed by promoter analyses. This in vitro model mimics the expression pattern of gastrin and insulin observed during fetal islet cell development and provides an excellent tool to analyse the molecular mechanisms controlling gastrin gene activation and selective repression during islet cell differentiation.


Subject(s)
Butyrates/pharmacology , Gastrins/drug effects , Gastrins/genetics , Islets of Langerhans/drug effects , Islets of Langerhans/pathology , Transcriptional Activation/drug effects , Animals , Antineoplastic Agents/pharmacology , Butyric Acid , Cell Differentiation/drug effects , Cell Differentiation/genetics , Cell Division/drug effects , Cricetinae , Gastrins/biosynthesis , Gene Expression Regulation, Neoplastic/drug effects , Islets of Langerhans/metabolism , Rats , Tumor Cells, Cultured
11.
Pancreas ; 14(3): 290-4, 1997 Apr.
Article in English | MEDLINE | ID: mdl-9094161

ABSTRACT

The respective cellular distribution of glucagon-like peptide-1 (GLP-1) immunoreactivity and mRNA expression of the GLP-1 receptor was compared in rat pancreas by means of immunohistochemistry and in situ hybridization. GLP-1 immunoreactivity was present in the marginal zone of rat pancreatic islets. In contrast, GLP-1 receptor mRNA signals were confined to the central part of pancreatic islets. Neither GLP-1 immunoreactivity nor GLP-1 receptor mRNA signals were detected in the exocrine pancreatic acinar cells or duct cells. The differential distribution of GLP-1 immunoreactivity and GLP-1 receptor mRNA signals indicates that the GLP-1 amino acid sequence is present in the alpha-cell zone of pancreatic islets, whereas the GLP-1 receptor is expressed mainly by beta cells. Thus, our data by in situ hybridization demonstrates the significant expression of GLP-1 receptors on beta cells but makes a significant expression on alpha cells rather unlikely.


Subject(s)
Islets of Langerhans/metabolism , Peptides/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , Receptors, Glucagon/genetics , Animals , Base Sequence , DNA Primers/genetics , Glucagon-Like Peptide 1 , Glucagon-Like Peptide-1 Receptor , Immunohistochemistry , In Situ Hybridization , Male , Polymerase Chain Reaction , Rats , Rats, Sprague-Dawley , Tissue Distribution
12.
Gastroenterology ; 112(3): 707-17, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9041231

ABSTRACT

BACKGROUND & AIMS: The mechanisms causing progression of fundic gastritis and changes in argyrophil cell morphology in patients undergoing long-term treatment with proton pump inhibitors are unknown. The hypothesis of this study was that Helicobacter pylori is a risk factor for both gastritis and argyrophil cell hyperplasia. METHODS: Forty-two patients with peptic disorders resistant to H2-blockers were treated with 30-90 mg lansoprazole daily for up to 5 years. Serum gastrin levels, antral gastrin cells, fundic argyrophil cells, parameters of gastritis, and H. pylori infection were evaluated regularly. RESULTS: In nonantrectomized patients, serum gastrin levels increased from a median of 76 pg/mL to 163 pg/mL within 3 months. Antral gastrin cell density increased from 175 to 267 cells/mm2 (P < 0.001), and fundic argyrophil cell density increased from 83 to 149 cells/mm2 (P < 0.001). Chronic inflammation, activity, and atrophy of the oxyntic mucosa worsened exclusively in patients with H. pylori infection. Linear and/or micronodular argyrophil cell hyperplasia was diagnosed in 2.6% of patients before lansoprazole and in 29.2% after 5 years treatment. These changes were significantly related to serum gastrin levels, H. pylori infection, chronic inflammation, and atrophy of the oxyntic mucosa. CONCLUSIONS: H. pylori represents an important factor for the progression of fundic gastritis and the development of argyrophil cell hyperplasia during long-term treatment with lansoprazole.


Subject(s)
Gastric Mucosa/drug effects , Helicobacter Infections/complications , Helicobacter pylori , Omeprazole/analogs & derivatives , Proton Pump Inhibitors , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Aged , Female , Gastric Mucosa/pathology , Gastrins/blood , Gastritis/chemically induced , Gastritis/pathology , Humans , Hyperplasia , Lansoprazole , Male , Middle Aged , Omeprazole/adverse effects , Pyloric Antrum/surgery , Risk Factors
13.
Digestion ; 58(3): 240-8, 1997.
Article in English | MEDLINE | ID: mdl-9243119

ABSTRACT

To evaluate whether the small bowel can be distracted by mechanical stress in analogy to limb lengthening by osteodistraction, a gut-lengthening apparatus was designed. This distractor was placed at the antimesenterical side of a defined jejunum segment in rabbits. Distraction was performed by 1 mm lengthening of the distractor once daily using extracorporal screws. An effective gut lengthening was achieved of 9.9 +/- 0.5 mm (approximately 100%) within 3 weeks. Treated animals gained weight and remained in good general condition. Fasting plasma levels of cholecystokinin, neurotensin, glucagon-like peptide-1, gastric inhibitory polypeptide, and insulin remained unaffected. Postoperative factor XIII levels were significantly diminished and gastrin was elevated during gut distraction. DNA and protein concentrations in the mucosa of the distracted gut segments corresponded to controls. Mucosal lactase and saccharase activities were reduced. In the distracted bowel segments total tunica muscularis thickness was more than doubled due to muscle cell hypertrophy. In distracted segments villous width was increased. Detection of proliferating mucosal crypt cells utilizing BrdUrd labeling revealed no effects. In conclusion, small gut lengthening by mechanical distraction is possible without major changes in gut morphology. This technique may hint a novel experimental approach for the treatment of short bowel syndrome.


Subject(s)
Intestine, Small/surgery , Short Bowel Syndrome/surgery , Animals , DNA/metabolism , Disease Models, Animal , Factor XIII/metabolism , Gastrins/blood , Immunohistochemistry , Intestinal Mucosa/metabolism , Intestinal Mucosa/pathology , Intestine, Small/metabolism , Intestine, Small/pathology , Lactase , Male , Muscle, Smooth/pathology , Organ Size , Rabbits , Short Bowel Syndrome/metabolism , Short Bowel Syndrome/pathology , Short Bowel Syndrome/therapy , Stress, Mechanical , Sucrase/metabolism , beta-Galactosidase/metabolism
15.
Eur J Gastroenterol Hepatol ; 8(9): 915-8, 1996 Sep.
Article in English | MEDLINE | ID: mdl-8889461

ABSTRACT

OBJECTIVE AND DESIGN: The effect of increasing doses of pantoprazole, a newly developed proton pump inhibitor, given at once daily doses of 40, 80 and 120 mg, on intragastric pH and serum gastrin profiles was studied in 15 healthy subjects in a randomized, double-blind, crossover study and compared to recordings without therapy. Measurements of intragastric pH and serum gastrin were performed on the 7th day of treatment by continuous pH recording and radioimmunoassay in blood samples obtained in 1-h intervals, respectively. RESULTS: Pantoprazole significantly increased gastric pH above basal at all pantoprazole doses studied: median 24-h pH rose from 1.2 without therapy to 3.4, 3.3 and 3.6 at 40, 80 and 120 mg daily, respectively. The corresponding integrated 24-h gastrin output was 1632, 2338 and 2248 pg/ml x 24 h compared to 575 pg/ml x 24 h without pantoprazole. There was no interindividual correlation between values of 24-h median pH and 24-h gastrin output at any pantoprazole dose studied. However, fasting gastrin levels closely correlated with 24-h gastrin output (r = 0.789; P < 0.0001). The acid inhibitory effect was significantly (P < 0.01) augmented in Helicobacter pylori positive subjects. CONCLUSION: It is concluded that pantoprazole is an effective inhibitor of gastric acid secretion. Increasing a single pantoprazole dose above 40 mg does not lead to increased median pH elevation. The individual extent of acid inhibition does not predict the magnitude of gastrin elevation. Acid inhibition appears more efficient in Helicobacter pylori positive subjects.


Subject(s)
Anti-Ulcer Agents/administration & dosage , Benzimidazoles/administration & dosage , Gastric Acid/metabolism , Proton Pump Inhibitors , Sulfoxides/administration & dosage , 2-Pyridinylmethylsulfinylbenzimidazoles , Adult , Anti-Ulcer Agents/therapeutic use , Benzimidazoles/therapeutic use , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Female , Gastrins/blood , Humans , Hydrogen-Ion Concentration , Male , Omeprazole/analogs & derivatives , Pantoprazole , Sulfoxides/therapeutic use
16.
Dtsch Med Wochenschr ; 121(8): 231-6, 1996 Feb 23.
Article in German | MEDLINE | ID: mdl-8815022

ABSTRACT

HISTORY AND FINDINGS: A now 54-year-old woman was 32 years ago found to have immune thrombocytopenia and 3 years ago ANA-positive and HBsAg-negative hepatitis with cirrhotic metaplasia. Numerous small asymptomatic carcinoids with marked hypergastrinaemia (1626 ng/l) were also first found 3 years ago. No gastrinoma could be found. Severe arthralgia was the main symptom on admission. INVESTIGATIONS: Gastroscopy revealed a polypoid carcinoid, 1 cm in diameter. There was total achlorhydria. No pernicious anaemia or carcinoid syndrome was found. TREATMENT AND COURSE: Total gastrectomy with construction of a jejunal substitute stomach was performed. Histology showed typical chronic-atrophic gastritis type A, all stages of an argyrophilic endocrine cell hyperplasia, as well as microcarcinoidosis and multicentric carcinoid, in part with submucosal infiltration and lymph node metastases. Immunohistology revealed immune reaction for the global endocrine marker. No specific hormones were demonstrable in the carcinoid cells. The postoperative course was without complications. Serum gastrin levels have since been normal. CONCLUSIONS: The case confirms the possibility of an achlorhydria-hypergastrinaemia-carcinoid sequence. Now new stage-related therapeutic guidelines for this disease are needed.


Subject(s)
Autoimmune Diseases , Carcinoid Tumor/etiology , Gastritis, Atrophic/complications , Stomach Neoplasms/etiology , Achlorhydria/complications , Carcinoid Tumor/pathology , Carcinoid Tumor/surgery , Female , Follow-Up Studies , Gastrectomy , Gastrins/blood , Gastroenterostomy , Humans , Jejunum/surgery , Lymphatic Metastasis , Middle Aged , Stomach/pathology , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Time Factors
17.
Chirurg ; 67(1): 1-6, 1996 Jan.
Article in German | MEDLINE | ID: mdl-8851668

ABSTRACT

In the past gastric acid was considered to be the major factor in the pathogenesis of peptic ulcers. For the first time bacteria were found in the stomach at the end of the last century. However, Helicobacter pylori could be detected and characterized not before 1983. Specific factors of virulence enable H. pylori to colonize the gastric mucosa. Infection occurs during childhood and due to a cohort-phenomenon the prevalence increases continuously with age. H. pylori infection can be diagnosed in about 95% of patients with duodenal ulcer and 70% of gastric ulcers. The important pathogenetic role of H. pylori infection could be demonstrated in eradication trials. According to our present knowledge gastric acid and H. pylori are independent prerequisits in peptic ulcer pathogenesis. H. pylori negative ulcer derive from NSAIDs or from the rare Zollinger-Ellison syndrome.


Subject(s)
Duodenal Ulcer/microbiology , Helicobacter Infections/microbiology , Helicobacter pylori , Stomach Ulcer/microbiology , Adolescent , Adult , Aged , Child , Cohort Studies , Gastric Mucosa/microbiology , Helicobacter pylori/isolation & purification , Helicobacter pylori/pathogenicity , Humans , Middle Aged , Virulence
18.
Digestion ; 57(5): 349-55, 1996.
Article in English | MEDLINE | ID: mdl-8886579

ABSTRACT

The colon contains large numbers of endocrine cells. Insight into their physiological function is limited. This is due to the fact that no sufficient model of isolated endocrine colon cells is available. In the present study we introduce an isolated vascularly perfused colon model for in vitro studies. This model offers the advantage that it keeps the endocrine cells in their physiological orientation and environment. The gut mucosa is highly sensitive to ischemia. Therefore, a careful validation of its viability is crucial in gut organ preparations. This study demonstrates that, by utilizing an oxygenated vascular medium supplemented with 25% washed bovine erythrocytes, a perfusion of the colon is achieved for at least 1 h without obvious tissue injuries. During this time parameters such as perfusion pressure, venous lactate dehydrogenase release, glucose consumption, lactate output, oxygen consumption, perfusate loss by the preparation and morphology were analyzed. Dependent on stimulation, the endocrine L cells of the colon released glucagon-like peptide-I upon arterial perfusion of methacholine or gastrin-releasing peptide. In conclusion, a model for the isolated perfusion of the colon is introduced which is suitable for studies of endocrine colon cells.


Subject(s)
Colon/blood supply , Animals , Cell Survival , Colon/cytology , Glucagon/metabolism , Glucagon-Like Peptide 1 , Glucose/metabolism , In Vitro Techniques , Intestinal Mucosa/cytology , L Cells/metabolism , L-Lactate Dehydrogenase/blood , Lactates/metabolism , Male , Mice , Oxygen Consumption , Peptide Fragments/metabolism , Perfusion , Protein Precursors/metabolism , Rats , Rats, Wistar
SELECTION OF CITATIONS
SEARCH DETAIL
...